Amgen may have a tough time getting FDA approval for trebananib without a survival benefit.
Combinations of various Vertex drugs could benefit 90% of cystic fibrosis patients.
In a bubbly year for the biotech sector, these five stocks stand out over the rest.
Ampio attacks critics instead of answering legitimate questions.
Biotech columnist Adam Feuerstein answers readers' questions about healthcare companies.
Amarin's president says company is preparing for FDA advisory panel seeking expansion of fish-oil pill's use.
The failure of a kidney cancer drug won't stop Aveo executives from cashing future paychecks.
Surprisingly strong results for a lung cancer drug have helped Clovis double in value today.
A narrowing of the survival benefit plus competition from anti-PD1s makes Synta's ganetespib success a long shot.
The anti-PD-1s are shrinking tumors like no drugs have done before and investors are really excited.